| Editor's Note: We will not publish Monday, Jan. 17 in observance of Martin Luther King Jr. Day . We will return to your inboxes on Tuesday, Jan. 18. - JPM 2022: Licensing and research tie-ups trump M&A at conference in 'reflection of last year'
- Biogen compiles buyout target list as Aduhelm woe deepens: Stat
- JPM 2022: Morgan Health, Kaiser Permanente partner on health equity
- Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirection
- JPM 2022: Bausch + Lomb files IPO for its eye care spinout
- HHS renews COVID-19 public health emergency order for another 90 days
- JPM 2022: With Voxzogo approvals adding up, BioMarin is underway with its 'biggest launch,' CEO says
- 'Shots on goal' to 'deterministic' drug development: Flagship CEO, Moderna Chair Noubar Afeyan pens first annual letter
- Genentech, American Cancer Society flash back to the '70s in PSA to destigmatize lung cancer, encourage screenings
- Verana Health lands J&J, Novo backing in $150M round to fund real-world database for drug, device development
- Bristol Myers plays it safe with first Zeposia TV ad for ulcerative colitis
- MedPAC declines to recommend to Congress additional pay bumps for doctors, hospitals
- JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO space
- Medtronic projects pain relief, longer battery life with low-power spinal cord stimulation
Featured Story | By Kyle LaHucik Just like at last year's J.P. Morgan Healthcare Conference, M&A is so 2019. In the third winter of COVID-19, the drug development world hasn’t executive on the type of megamergers we saw in 2019, such as Bristol Myers Squibb’s $74 billion Celgene deal, which dropped in the lead up to the healthcare industry's largest gathering. read more |
| |
|---|
|
Top Stories By Angus Liu Biogen has found itself increasingly deeper in the quagmire that is the Alzheimer’s disease drug Aduhelm. Like any beleaguered company might do, the Big Biotech is weighing some strategic options, according to a Stat report. read more By Paige Minemyer Beginning this month, JPMorgan Chase's some 8,000 California employees will be able to access care through Kaiser Permanente, and the partnership will put a focus on health disparities. read more By Fraiser Kansteiner Novo Nordisk investors sued in Denmark in Aug. 2019, alleging the company made “misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the US,” Novo said. The original claim demanded Novo Nordisk pay 11.78 billion Danish krone (about $1.8 billion) in compensation. read more By Conor Hale Nearly 18 months after announcing plans to spin out its eye health business, Bausch + Lomb has filed the paperwork for an IPO on both the New York and Toronto stock exchanges. read more By Robert King HHS Secretary Xavier Becerra renewed the COVID-19 public health emergency for another 90 days, extending major flexibilities to providers. read more By Eric Sagonowsky BioMarin has plenty of experience launching rare disease drugs, but the company's newest rollout will feature some notable differences from its prior marketing efforts. All things considered, it's a launch BioMarin CEO Jean-Jacques Bienaimé thinks could become the biggest in the "history of the company.” read more By Kyle LaHucik Written in the middle of the largest pandemic wave to-date, Flagship Pioneering CEO and Moderna Chairman Noubar Afeyan, Ph.D., penned his first annual letter documenting the sea changes in biotech. He also called on more preemptive measures for future pandemics and tackling the underlying diseases of common illnesses. read more By Natalie Missakian It was the era of bell-bottoms, 8-track tapes, jello molds and the Hustle—and a time when it seemed like everyone, everywhere smoked. Genentech and the American Cancer Society appeal to ex-smokers in a campaign to destigmatize lung cancer and boost regular screenings. read more By Andrea Park With a new CEO at the helm, the recent launch of an artificial-intelligence-powered data analytics engine and, now, the close of its largest funding round to date, Verana Health appears ready to make good on its promise to revolutionize both drug development and healthcare delivery. read more By Ben Adams “I won’t let UC stop me from being me,” says a handsome middle-aged father as he travels from the airport to the great outdoors in a fairly classic, no frills advert for Zeposia, Bristol Myers Squibb’s new ulcerative colitis drug. But it seems like old hat compared to the campaigns we saw in 2021 from rivals. read more By Robert King MedPAC did not recommend that Congress make any additional payments in 2023 to hospitals and doctors beyond current law, noting that targeted relief payments have helped blunt the financial impact of COVID-19. read more By Gareth Macdonald Resurgent demand was a common theme for CROs presenting at the J.P. Morgan Healthcare Conference with Icon, Syneos and PPD owner Thermo Fisher daring to look beyond the pandemic toward changing industry needs. read more By Conor Hale Medtronic delivered new clinical data demonstrating improved relief from chronic pain using a modified, low-power version of its spinal cord stimulation therapy, potentially enabling fewer recharges or a longer overall battery life. read more |
